evoke semaglutide and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of in early-stage symptomatic Alzheimer's disease | Alzheimer's Research & Therapy EVOKE/EVOKE+ - Neuroprogressive and Dementia

Despite an emerging consensus that these peripherally administered GLP1RAs exert their effects on appetite suppression through the central nervous system, knowledge of the neural pathways and intracellular signaling mechanisms by which they act in the brain remains limited

2005 Jan-Feb;40(1-2):51-7

Be mindful of companies that try to sell weight loss solutions that sound too good to be true

"One tool does not work for each person, and one tool often is not enough over the lifetime of a person to control or to mitigate the health impact of that condition," she says

At Ro, were working to take the stress and guesswork out of the process